Cargando…

Efficacy and Safety of Intravesical OnabotulinumtoxinA Injection on Elderly Patients with Chronic Central Nervous System Lesions and Overactive Bladder

PURPOSE: Intravesical injection of onabotulinumtoxinA is an effective treatment for overactive bladder (OAB). Nonetheless, the treatment outcome is unclear in OAB patients with central nervous system (CNS) lesions. This study evaluated the efficacy and safety of intravesical onabotulinumtoxinA treat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Yuan-Hong, Liao, Chun-Hou, Tang, Dong-Ling, Kuo, Hann-Chorng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4141863/ https://www.ncbi.nlm.nih.gov/pubmed/25148378 http://dx.doi.org/10.1371/journal.pone.0105989

Ejemplares similares

Factors Associated with Therapeutic Efficacy of Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Syndrome
por: Hsiao, Sheng-Mou, et al.
Publicado: (2016)

Adverse Events of Intravesical OnabotulinumtoxinA Injection between Patients with Overactive Bladder and Interstitial Cystitis—Different Mechanisms of Action of Botox on Bladder Dysfunction?
por: Kuo, Yuh-Chen, et al.
Publicado: (2016)

Urodynamic prognostic factors for large post-void residual urine volume after intravesical injection of onabotulinumtoxinA for overactive bladder
por: Hsiao, Sheng-Mou, et al.
Publicado: (2017)

Efficacy and Safety of Intravesical OnabotulinumtoxinA Injection in Patients with Detrusor Hyperactivity and Impaired Contractility
por: Wang, Chung-Cheng, et al.
Publicado: (2016)

Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Patients with Frailty, Medical Comorbidities or Prior Lower Urinary Tract Surgery
por: Liao, Chun-Hou, et al.
Publicado: (2016)

Intravesical OnabotulinumtoxinA Injection for Overactive Orthotopic Ileal Neobladder: Feasibility and Efficacy
por: Hoag, Nathan, et al.
Publicado: (2016)

OnabotulinumtoxinA for the treatment of overactive bladder
por: Cox, Lindsey, et al.
Publicado: (2014)

Novel Treatment of Chronic Bladder Pain Syndrome and Other Pelvic Pain Disorders by OnabotulinumtoxinA Injection
por: Jhang, Jia-Fong, et al.
Publicado: (2015)

Effectiveness and Safety of Intradetrusor OnabotulinumtoxinA Injection for Neurogenic Detrusor Overactivity and Overactive Bladder Patients in Taiwan—A Phase IV Prospective, Interventional, Multiple-Center Study (Restore Study)
por: Wang, Chung-Cheng, et al.
Publicado: (2021)

Bleeding risk in female patients undergoing intravesical injection of onabotulinumtoxinA for overactive bladder: a Danish retrospective cohort study
por: El Issaoui, Meryam, et al.
Publicado: (2023)

Reduced versus standard intradetrusor OnabotulinumtoxinA injections for treatment of overactive bladder
por: DiCarlo‐Meacham, Angela M., et al.
Publicado: (2022)

Efficacy of Intravesical Botulinum Toxin A Injection in the Treatment of Refractory Overactive Bladder in Children
por: Fan, Yu-Hua, et al.
Publicado: (2023)

Satisfaction with Detrusor OnabotulinumtoxinA Injections and Conversion to Other Bladder Management in Patients with Chronic Spinal Cord Injury
por: Chen, Sheng-Fu, et al.
Publicado: (2022)

Long-Term Efficacy and Safety of Repeated Intravescial OnabotulinumtoxinA Injections Plus Hydrodistention in the Treatment of Interstitial Cystitis/Bladder Pain Syndrome
por: Lee, Cheng-Ling, et al.
Publicado: (2015)

Novel Applications of OnabotulinumtoxinA in Lower Urinary Tract Dysfunction
por: Jhang, Jia-Fong, et al.
Publicado: (2018)

The clinical application of intravesical botulinum toxin A injection in patients with overactive bladder and interstitial cystitis
por: Jiang, Yuan-Hong, et al.
Publicado: (2022)

New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA
por: Andersson, Karl-Erik
Publicado: (2013)

von Brunn's Nests and Follicular Cystitis Following Intradetrusor OnabotulinumtoxinA Injections for Overactive Bladder
por: Nekkanti, Silpa, et al.
Publicado: (2017)

Are we underestimating urinary retention following intravesical onabotulinumtoxinA in women with overactive bladder and a history of prior pelvic surgery?
por: Holmes, Angela, et al.
Publicado: (2022)

Treatment of neurogenic detrusor overactivity and overactive bladder with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Nitti, Victor, et al.
Publicado: (2023)

The satisfaction of patients with refractory idiopathic overactive bladder with onabotulinumtoxinA and augmentation cystoplasty
por: El-Azab, Ahmed S., et al.
Publicado: (2013)

Comparative assessment of onabotulinumtoxinA and mirabegron for overactive bladder: an indirect treatment comparison
por: Freemantle, Nick, et al.
Publicado: (2016)

Clinical application of intravesical botulinum toxin type A for overactive bladder and interstitial cystitis
por: Chen, Jing-Liang, et al.
Publicado: (2020)

OnabotulinumtoxinA for the treatment of neurogenic detrusor overactivity in children
por: Austin, Paul F., et al.
Publicado: (2020)

Intravesical Loss of OnabotulinumtoxinA During Endoscopic Intradetrusor Injection - A Multicenter Experience
por: Šámal, Vladimír, et al.
Publicado: (2020)

Intravesical injection of onabotulinumtoxinA in neurogenic overactive bladder patients with human T‐cell leukemia virus type 1‐associated myelopathy: A single‐institution case series
por: Matsuo, Tomohiro, et al.
Publicado: (2021)

A Feasibility Study to Evaluate Changes in Urinary Metabolites after OnabotulinumtoxinA Injection for Refractory Overactive Bladder
por: Tellechea, Laura M., et al.
Publicado: (2022)

Neurogenic overactive bladder in spinal cord injury and multiple sclerosis: role of onabotulinumtoxinA
por: Ethans, KD, et al.
Publicado: (2014)

OnabotulinumtoxinA Urethral Sphincter Injection as Treatment for Non-neurogenic Voiding Dysfunction – A Randomized, Double-Blind, Placebo-Controlled Study
por: Jiang, Yuan-Hong, et al.
Publicado: (2016)

Intravesical Injection of Botulinum Toxin Type A in Patients with Refractory Overactive Bladder—Results between Young and Elderly Populations, and Factors Associated with Unfavorable Outcomes
por: Ou, Yin-Chien, et al.
Publicado: (2023)

OnabotulinumtoxinA in the treatment of neurogenic bladder
por: Gulamhusein, Aziz, et al.
Publicado: (2012)

Cost-Utility Analysis of Oxybutynin vs. OnabotulinumtoxinA (Botox) in the Treatment of Overactive Bladder Syndrome
por: Shabir, Habiba, et al.
Publicado: (2021)

300 IU vs. 200 IU of OnabotulinumtoxinA for detrusor overactivity
por: Persu, Cristian
Publicado: (2014)

Trigonal-Sparing vs. Trigonal-Involved OnabotulinumtoxinA Injection for the Treatment of Overactive Bladder: A Systematic Review and Meta-Analysis
por: Cui, Yuanshan, et al.
Publicado: (2021)

OnabotulinumtoxinA is a well tolerated and effective treatment for refractory overactive bladder in real-world practice
por: Hamid, Rizwan, et al.
Publicado: (2020)

Individualizing medical treatment of overactive bladder
por: Kuo, Hann-Chorng
Publicado: (2018)

Efficacy and safety of intradetrusor onabotulinumtoxinA injection for managing paediatric non-neurogenic overactive bladder: A prospective case-series study
por: El-Dakhakhny, Amr S., et al.
Publicado: (2019)

OnabotulinumtoxinA for neurogenic detrusor overactivity and dose differences: a systematic review
por: Zhang, Rui, et al.
Publicado: (2015)

Practical Aspects of Botulinum Toxin-A Treatment in Patients With Overactive Bladder Syndrome
por: Liao, Chun-Hou, et al.
Publicado: (2015)

The Effects of Age, Gender, and Postvoid Residual Volume on Catheterization Rates After Treatment with OnabotulinumtoxinA for Overactive Bladder
por: Dmochowski, Roger, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_pukqb2sa04f4otmvtactappubh